Who: GSK/Johnson & Johnson/Arrowhead
What: GSK is assuming the rights to a Phase II siRNA candidate for hepatitis B that Arrowhead previously licensed to...
GSK Takes Over J&J/Arrowhead Hep B Candidate For Combo Development
Deal Snapshot: Seeking to develop a combination regimen for chronic hepatitis B, GSK acquires rights to J&J/Arrowhead’s siRNA candidate JNJ-3839 to pair with its antisense candidate bepiroversen.
More from Deals
• By
The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.
• By
Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.
• By
Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.
• By
The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.